PepGen Inc. (PEPG) has a MoatMap StockRank of 6/100 based on Quality (34/100), Value (42/100), and Momentum (9/100) factor scores. The current signal is STRONG SELL. Clinical-stage biotechnology company focused on neuromuscular diseases, presenting binary clinical trial risk and zero current revenues.
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular diseases, including Duchenne muscular dystrophy. Its proprietary Enhanced Delivery Oligonucleotide (EDO) platform aims to improve the intracellular delivery of therapies. The company's competitive advantage lies in its innovative drug delivery technology designed to overcome existing limitations in RNA-based therapeutics.
| Price | $1.38 |
| Market Cap | $104M |
| P/E (Forward) | -1.15 |
| Price/Book | 0.76 |
| Return on Equity | -68.4% |
| Return on Invested Capital | -58.0% |
| Debt/Equity | 12.36 |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
| Free Cash Flow | $-49M |
PepGen Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).